Ipsen to start second resupply of Increlex in the US in September
In collaboration with the US Food and Drug Administration (FDA), Ipsen is releasing a second batch of Increlex in 2014. The first batch was made available for distribution
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Aripiprazole lauroxil is an investigational, new, once-monthly, long-acting injectable atypical antipsychotic. The NDA is based on the positive results from the randomized, multicenter, double-blind, placebo-controlled, phase III trial